Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Q2 2024 Earnings Presentation
11 slides from Bionano Genomics's earnings presentation, Aug 7, 2024
Slide 1: Q2 2024 Financial Results Webcast & Call
Q2 2024 Financial Results Webcast & Call August 7th 2024
Slide 2: Safe harbor statement
Safe harbor statement - This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan," anticipate,” “estimate,” “intend,” “should,” “believe,” “would,” “could,” “potential,” “outlook,” “
Slide 3: Significant milestone for OGM with establishment of Category I CPT code
Significant milestone for OGM with establishment of Category I CPT code for OGM in hematological malignancy analysis • Editorial panel of the American Medical American Medical Association (AMA) CPT Code for OGM Association (AMA) established a new Category I Current Procedural Terminology Code # 88XX
Slide 4: Corporate Update
Corporate Update R. Erik Holmlin CEO eholmlin@bionano.com 4
Slide 5: Q2 2024 Business Highlights
Q2 2024 Business Highlights Entered into software marketing • Q2 2024 revenue was $7.8 million, a agreement with Revvity, Inc. under which Revvity will market and commercialize VIA as part its newborn decrease of 10% from Q2 2023 sequencing research workflow • Q2 2024 OGM installed base grew to PUBL
Slide 6: Financial Overview
Financial Overview Gülsen Kama CFO gkama@bionano.com 6
Slide 7: Q2 2024 Financial Highlights
Q2 2024 Financial Highlights • Q2 revenues: $7.8M (-10% vs Q2’23) • GAAP gross margin of 33%; non-GAAP gross margin 35% • GAAP OpEx $19.6M; non-GAAP OpEx $18.8M • Q2 OGM installed base: 363 (+29% vs Q2’23) • Q2 flowcells sold: 6,165 (-13% vs Q2’23) $30.3M* Cash, Cash Equivalents, and Available-for-S
Slide 8: Important steps to help us deliver against our vision
Important steps to help us deliver against our vision Debt Restructuring Completed Private Placement of Sr. Sec Notes Due May 2026 ($20M principal amount) in May 2024 Proceeds used to completely retire the October 2023 convertible debt facility Equity Financing Registered direct offering in Ap
Slide 9: Streamlined business focus and 2024 guidance
Bionano is focused on accelerating revenue growth, operating efficiently, and raising capital that will allow us to extend our cash runway Streamlined Business Focus 2024 Guidance • Ramp commercialization of Stratys OGM FY’24 Total Revenue Guidance: & drive adoption of VIA software $36-$40M • Advanc
Slide 10: Questions & Answers
Questions & Answers Contact: R. Erik Holmlin Gülsen Kama CEO CFO eholmlin@bionano.com gkama@bionano.com 10
Slide 11: Thank you.
= Thank you.